ArticleIBRO neuroscience reports2025
Neuroprotection and activation of anti-inflammatory and plasticity mechanisms by PLC-β inhibition after cholinergic hyperstimulation in hippocampal slices and microglial cells.
Article in IBRO neuroscience reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Epilepsy, a chronic neurological disorder characterized by recurring seizures, involves inflammatory and abnormal plasticity features. Current treatments, primarily combinations of anticonvulsant drugs, often carry adverse effects, and a substantial portion of patients remain resistant to available therapies. In this study, we used the muscarinic agonist pilocarpine (Pilo) to probe epileptogenesis mechanisms and explore the effects of edelfosine (Ef), a synthetic alkyl-lysophospholipid (ALP), and phospholipase C (PLC)-β inhibitor, as a potential anti-epileptic agent. By targeting PLC-β activation, a link between muscarinic stimulation and brain injury, we assessed edelfosine's neuroprotective effects in an ex-vivo Pilo model. Ef, at 1 and 10 μM, significantly preserved neuronal PS in hippocampal slices compared to controls. Additionally, Ef (1 μM) in vitro studies demonstrated a reduction in proinflammatory gene expression, tumor necrosis factor-α (
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.